Stock Track | BillionToOne Soars 6.40% After-Hours on Strong Q4 Results and Raised 2026 Guidance

Stock Track03-05

BillionToOne, Inc. (NASDAQ: BLLN) experienced a significant after-hours surge of 6.40% on Wednesday, following the release of its fourth quarter and full year 2025 financial results.

The molecular diagnostics company reported quarterly earnings of $0.11 per share, which substantially beat the analyst consensus estimate of $0.03. This represents a dramatic swing from a loss of $1.13 per share in the same period last year. Quarterly sales reached $96.053 million, surpassing estimates of $87.161 million and marking a 113% year-over-year increase.

Furthermore, the company raised its full-year 2026 revenue guidance to a range of $430 million to $445 million, up from its previous outlook of $415 million to $430 million and well above the FactSet estimate of $405.1 million. BillionToOne also stated it expects positive GAAP operating income for the full year 2026, driven by strong growth in both its prenatal and oncology clinical testing segments.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1103183292?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-05 05:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1103183292","market":"hk","top_or_hot":-1,"title":"Stock Track | BillionToOne Soars 6.40% After-Hours on Strong Q4 Results and Raised 2026 Guidance","media":"Stock Track","content":"<p>BillionToOne, Inc. (NASDAQ: BLLN) experienced a significant after-hours surge of 6.40% on Wednesday, following the release of its fourth quarter and full year 2025 financial results.</p><p>The molecular diagnostics company reported quarterly earnings of $0.11 per share, which substantially beat the analyst consensus estimate of $0.03. This represents a dramatic swing from a loss of $1.13 per share in the same period last year. Quarterly sales reached $96.053 million, surpassing estimates of $87.161 million and marking a 113% year-over-year increase.</p><p>Furthermore, the company raised its full-year 2026 revenue guidance to a range of $430 million to $445 million, up from its previous outlook of $415 million to $430 million and well above the FactSet estimate of $405.1 million. BillionToOne also stated it expects positive GAAP operating income for the full year 2026, driven by strong growth in both its prenatal and oncology clinical testing segments.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | BillionToOne Soars 6.40% After-Hours on Strong Q4 Results and Raised 2026 Guidance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | BillionToOne Soars 6.40% After-Hours on Strong Q4 Results and Raised 2026 Guidance\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-03-05 05:38</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>BillionToOne, Inc. (NASDAQ: BLLN) experienced a significant after-hours surge of 6.40% on Wednesday, following the release of its fourth quarter and full year 2025 financial results.</p><p>The molecular diagnostics company reported quarterly earnings of $0.11 per share, which substantially beat the analyst consensus estimate of $0.03. This represents a dramatic swing from a loss of $1.13 per share in the same period last year. Quarterly sales reached $96.053 million, surpassing estimates of $87.161 million and marking a 113% year-over-year increase.</p><p>Furthermore, the company raised its full-year 2026 revenue guidance to a range of $430 million to $445 million, up from its previous outlook of $415 million to $430 million and well above the FactSet estimate of $405.1 million. BillionToOne also stated it expects positive GAAP operating income for the full year 2026, driven by strong growth in both its prenatal and oncology clinical testing segments.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BLLN","symbol_name":"BillionToOne, Inc.","start_time":0,"source_url":"","article_id":"1103183292","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1103183292","pubTimestamp":1772660336,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"BillionToOne, Inc. (NASDAQ: BLLN) experienced a significant after-hours surge of 6.40% on Wednesday, following the release of its fourth quarter and full year 2025 financial results.The molecular...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BLLN":"BillionToOne, Inc."},"translate_title":"个股赛道|BillionToOne盘后大涨6.40%Q4业绩强劲上调2026年指引","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BLLN":1},"content_text":"BillionToOne, Inc. (NASDAQ: BLLN) experienced a significant after-hours surge of 6.40% on Wednesday, following the release of its fourth quarter and full year 2025 financial results.The molecular diagnostics company reported quarterly earnings of $0.11 per share, which substantially beat the analyst consensus estimate of $0.03. This represents a dramatic swing from a loss of $1.13 per share in the same period last year. Quarterly sales reached $96.053 million, surpassing estimates of $87.161 million and marking a 113% year-over-year increase.Furthermore, the company raised its full-year 2026 revenue guidance to a range of $430 million to $445 million, up from its previous outlook of $415 million to $430 million and well above the FactSet estimate of $405.1 million. BillionToOne also stated it expects positive GAAP operating income for the full year 2026, driven by strong growth in both its prenatal and oncology clinical testing segments.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1103183292","isCrawlerRequest":true}